Ohio State Early Investor Network Disclaimer

OSEIN does not provide investment advice, and the information contained in this memo should not be solely relied upon for making investment decisions. Investors are encouraged to conduct their own due diligence and seek professional advice before making any investment. OSEIN does not assume any liability or responsibility for investment outcomes. Additionally, AI was used to review, synthesize, and prepare the following information.

Investing in early-stage and angel investments is inherently risky, and investors should be aware that they may lose their entire investment. By proceeding with any investment, investors acknowledge and assume these risks and understand that the outcomes can be unpredictable and may not result in financial gain.

Link: Pitch Recording (password: OSEIN)

Avionova Follow-Up Questions

April 10, 2026 Updates:

Product & Engineering Progress

We’ve completed our Asterra benchmark testing, and Gravitone 2.0 is now ready for wear testing. This version is currently being used as our internal testbed to inform both product performance and future medical development.

In parallel, Asterra 2.0 is entering small-scale manufacturing ahead of upcoming pilots. We are actively collecting vendor quotes and building out initial production capabilities in San Francisco. Early unit economics are shaping up as follows:

These early numbers give us confidence in both the near-term pilot model and long-term scalability.

Application Development

We’ve also developed a companion application in collaboration with Ohio State capstone students. The app predicts seasickness susceptibility using vessel data, geopositioning, and user demographics, and can prompt users to proactively use the device.

Longer term, we see this as both a product enhancement and a lightweight entry point for customer engagement—allowing us to build brand awareness even before direct device use.

Pilots & Industry Engagement

We’re currently finalizing pilot timelines for this summer, including:

The crew use case continues to stand out as particularly compelling. Many seafarers are restricted from using traditional motion sickness medications while on duty, creating a strong need for a non-pharmaceutical, real-time solution. We’re increasingly exploring how to position Asterra as both a safety and productivity tool in these environments.

On the commercial side, our perspective has evolved. While we initially focused on expedition and luxury segments, recent traction—especially following our engagement with the Cruise Line International Association (CLIA)—has opened conversations with larger operators including MSC Virgin Voyages, and Norwegian Cruise Line, as well as broader distribution groups.

We’re using this phase to intentionally test multiple segments (crew, medical, retail, expedition, and large cruise lines) before committing to a primary go-to-market path. I’ll be continuing these conversations this week at Seatrade in Miami.

Research Partnerships

We’re also launching a new research collaboration with the Reykjavik University Institute of Biomedical and Neural Engineering, alongside our ongoing work with Ohio State.

This work centers around BioVRSea, a virtual reality and motion-platform system that simulates maritime conditions in a controlled environment. It allows us to measure balance and postural responses using biosignals such as EMG, EEG, and heart rate.

This approach enables us to:

We’ll be in Reykjavik in May to begin early development work, followed by a 15–25 participant study shortly after.

Company: Avionova, Inc.

Website: https://www.avionova.tech/

LinkedIn: https://www.linkedin.com/company/avionova/

Pitch Deck

Intake Form

Financials

Basic Company Information